purine synthesis enzymes Inhibitors
2 drugsAbout purine synthesis enzymes
Purine synthesis enzymes are essential for creating purines, the building blocks of DNA and RNA, catalyzing reactions crucial for cell growth and proliferation. These enzymes are attractive targets for drug development, particularly in oncology, due to their fundamental role in cell division.
While there is currently no genetic evidence directly linking these enzymes to specific diseases, their fundamental role in cell division highlights their therapeutic potential. Targeting these enzymes can disrupt cell growth, making them relevant in oncology and other areas where controlling cell proliferation is beneficial.
Two FDA-approved drugs, PURIXAN and PURINETHOL, target purine synthesis enzymes for cancer treatment, both are small molecules. These drugs, developed by NOVA LABS LTD and STASON PHARMS, demonstrate the viability of this approach in oncology.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Refractory Acute Lymphoblastic Leukemia with only 2 trials.
- phase2 represents biological uncertainty with 42% completion.
Top purine synthesis enzymes Drugs
The competitive landscape includes two companies, NOVA LABS LTD and STASON PHARMS, with approved drugs.
Low market concentration suggests opportunities for new entrants, but high regulatory barriers exist.
purine synthesis enzymes Drug Modality Landscape
Modalities
Routes of Administration
purine synthesis enzymes is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
purine synthesis enzymes Clinical Trials 86 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 5 | 2 | 8 | 71% |
| Phase 2 | 44 | 12 | 7 | 25 | 63% |
| Phase 3 | 23 | 10 | 0 | 13 | 100% |
| Phase 4 | 4 | 4 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
purine synthesis enzymes Drug Approval Timeline (1953 - 2014)
The first drug was approved in 1953, and the most recent in 2014, spanning 62 years.
The long approval span indicates a mature target class, but recent approval suggests continued interest.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 63 clinical trials targeting purine synthesis enzymes.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities